Stryker receives subpoena and warning letter
This article was originally published in Clinica
Executive Summary
Orthopaedics firm Stryker has been handed a subpoena by the attorney general of New Jersey, requesting information relating to its financial relationship with physicians participating in certain clinical trials. The Kalamazoo, Michigan-based company is currently working on its response to the subpoena, which it claims has been issued to other major medical device manufacturing companies. Separately, Stryker has received a warning letter from the US FDA in relation to its craniomaxillofacial implant products. Full details of the warning were not disclosed and a spokesperson for the company told Clinica that it would not be making any further comments. Earlier this year, Stryker came under investigation from the US attorney’s office for the district of Massachusetts following claims of illegal and inaccurate promotion of its orthobiological products (see Clinica No 1336, p 3).
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals